High apolipoprotein E in cerebrospinal fluid of patients with Lewy body disorders is associated with dementia

• Published in: Alzheimer's & dementia Vol. 10; no. 5; pp. 530 - 540.e1
• Main Authors: Vijayaraghavan, Swetha, Maetzler, Walter, Reimold, Matthias, Lithner, Christina Unger, Liepelt-Scarfone, Inga, Berg, Daniela, Darreh-Shori, Taher
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.09.2014; ALZHEIMER'S & DEMENTIA
• Subjects: Aged; Aged, 80 and over; Alzheimer's disease; Amyloid beta-Peptides - cerebrospinal fluid; Amyloid beta-Protein Precursor - cerebrospinal fluid; Amyloid-β; Aniline Compounds; Apolipoprotein E; Apolipoproteins E - cerebrospinal fluid; Apolipoproteins E - genetics; Biomarkers - cerebrospinal fluid; Brain - diagnostic imaging; Brain - metabolism; Brain - pathology; Carbon Radioisotopes; Cerebrospinal fluid; Cohort Studies; Dementia with Lewy bodies; Female; Fluorodeoxyglucose F18; Fluorodeoxyglucose–positron emission tomography; Glucose - metabolism; Humans; Lewy Body Disease - cerebrospinal fluid; Lewy Body Disease - diagnostic imaging; Lewy Body Disease - genetics; Lewy Body Disease - psychology; Lewy body-associated disorders; Male; Medicin och hälsovetenskap; Middle Aged; Neurology; Neuropsychological Tests; Peptide Fragments - cerebrospinal fluid; Pittsburgh compound B–positron emission tomography; Positron emission tomography; Radiopharmaceuticals; tau Proteins - cerebrospinal fluid; Thiazoles; Alzheimer’s disease; Apolipoprotein E; Pittsburgh compound B–positron emission tomography; Lewy body-associated disorders; Fluorodeoxyglucose–positron emission tomography; Cerebrospinal fluid; Amyloid-β; Positron emission tomography; Dementia with Lewy bodies
• ISSN: 1552-5260; 1552-5279; 1552-5279
• DOI: 10.1016/j.jalz.2013.03.010

Abstract Apolipoprotein E ε4 allele ( APOE ε4) increases the apolipoprotein E (apoE) protein levels in Alzheimer’s disease (AD) cerebrospinal fluid (CSF). Thus, we hypothesized that apoE levels were also associated with the APOE genotype, and amyloid-β (Aβ)-associated clinical, functional, and imaging parameters in patients with Lewy body-associated disorders (LBD). Indeed, similar to AD, patients with LBD displayed high CSF apoE levels (greatest in patients with dementia with LBD), and this was linked to APOE ε4. High CSF apoE protein correlated positively with CSF soluble amyloid precursor protein, total tau, and cortical and striatal Pittsburgh compound B retention; and correlated negatively with CSF Aβ42 , cognitive tests scores, and glucose uptake ratio in the temporal and parietal cortices. APOE ε4-triggered accumulation of apoE in CSF is related to Aβ-associated clinical and functional imaging parameters in LBD. Accordingly, therapeutic strategies aimed at reducing apoE levels in the brain should be explored not only in AD but also in LBD, particularly when accompanied with dementia.